I-MED Pharma: Taking Eye Care to the Next Level

Today, the product is the most advanced eye drop for hydrating and lubricating the cornea. It stabilizes and enhances the lipid layer while reducing the evaporation of the tear film.

What’s more? I-DROP^® MGD is a long-lasting artificial tear with blink-activated coating and re-coating of the surface of the eye, resulting in increased patient comfort and lower therapy costs to patients. In contrast to other eye drops, a patient only needs to apply I-DROP^® MGD a few times per day. But what truly differentiates the eye drop from others in the landscape is the fact that it is stable at room temperature, transparent (i.e., short-term blurring), and delivers unparalleled ocular hydration and comfort. I-DROP^® MGD is most suited for patients with moderate to severe evaporative dry eye disease with a compromised lipid layer. “We are very proud of this product and we will continue to invest heavily into the education and R&D of new, effective dry eye products going forward,” informs Hofmann.

I-MED Pharma was first established in 1989 in Montreal, QC as a distributor of ophthalmic products for cataract and corneal surgery. “We slowly expanded our expertise to include researching, developing, and distributing additional innovative medical, surgical, and veterinary eye care products aligning with the needs of the market. We cater to the demands of the Canadian ophthalmologists, optometrists, and the global eye care community,” mentions Hofmann. “We consider ourselves as a science-based R&D company first, and a commercialization and marketing sales company second. We ensure that everything we develop and sell is top class.” Currently, I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene cleansers, nutritional supplements, dry eye drops, and therapeutic accessories. Over the last 30 years, the firm has brought over 40 different products from concept to market.

For the road ahead, the company will continue to develop the most innovative products and bring them to market. At the same time, I-MED Pharma is also planning on investing in advanced technology that will allow ophthalmologists and optometrists to diagnose eye conditions more safely, with less contact—accurately and quickly. Given the current pandemic and the increase in remote working, more people are spending a major part of their time in front of computer screens resulting in the development of both dry eye disease and computer vision syndrome (a subset of dry eye.) “Our aim is to help them with state-of-the-art diagnostics and effective treatment solutions and be acknowledged worldwide as the leading dry eye disease company,” wraps up Hofmann.